Interim results Q2 and H1 2013 Biotec Pharmacon

RESUME:

SECOND QUARTER HIGHLIGHTS

· Successfully validated the Woulgan® Biogel production and obtained
ISO 13485 certification
· Signed enzyme supply agreement with GE Healthcare Life Science
· Stable overall revenue and reduced losses compared to Q2 2013

OUTLOOK

· Awaiting decision regarding CE-marking of Woulgan® Biogel as medical
device
· Woulgan® Biogel product launch and market evaluation process with
Smith & Nephew to start upon CE-marking
· Expecting to sign more enzyme supply agreements with global leaders
in molecular biology
· Year-on-year increasing enzyme sales revenue in Q3

Please find enclosed the complete interim report for Q2 and H1 2013.

For further information, please contact:

Svein W. F. Lien - CEO: +47 922 89 323

The company hosts a presentation of the interim results on Friday, 9
August at 08:30, at Thon Conference Vika Atrium, Munkedamsveien 45,
Oslo. It will be possible to follow the presentation as live video
webcast with log on at www.biotec.no.